Lumicell Phase 1 Results Presented at SSO 2015 Annual Cancer Symposium

Phase 1 Results Also Presented at AACR 2015 Annual Meeting Wellesley, Mass., May 8, 2015 – Lumicell, a leader in the field of image-guided cancer surgery, announced that Phase 1 trial results were recently presented at the SSO 2015 Annual Cancer Symposium in March and the AACR 2015 Annual Meeting in April. Both sessions were presented by Lumicell’s clinical collaborators at Duke University Medical Center. Lumicell recently completed its Phase 1 safety study at Duke University Medical Center in the lead indications of breast cancer and sarcoma. The Phase 1 study of Lumicell’s leading imaging agent was completed with cancer patients under-going surgery. No imaging agent related adverse events were reported during the study, indicating the safety of Lumicell’s imaging agent. Lumicell is addressing the number one challenge in cancer surgery – the need to remove all cancer cells within the tumor bed during the first surgery. In the field of cancer surgery, the goal is clean margins. Lumicell’s intraoperative detection system provides surgeons with the needed tools to perform a thorough removal of any residual cancer cells in real-time within the tumor bed thus eliminating the need for repeat surgeries due to positive margins or local recurrence. Imaging results from the Phase 1 safety study demonstrate that Lumicell’s imaging agent provides excellent contrast between normal tissue and a tumor. Lumicell’s surgical system combines a lightweight hand-held single-cell detection imaging device and a cancer-specific molecular imaging agent. This image-guided technology is designed to fit within the existing surgical workflow. The company’s devices and imaging agents are optimized for the specific cancer-type and surgical procedure. The US Patent Office has allowed broad patent claims on both the device and the imaging agent which will provide excellent IP protection. Lumicell has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to launch a feasibility (pilot) study for intraoperative imaging of breast cancer during surgery. The study will be conducted at Massachusetts General Hospital (MGH). Further trial information can be found here: https://clinicaltrials.gov/show/NCT02438358. The Principal Investigator for the feasibility study is Dr. Barbara Smith, Director, Breast Cancer Program and Co-Director, Gillette Center for Women’s Cancer at MGH. About Lumicell, Inc. Lumicell is a leader in the field of image-guided cancer surgery. The company is developing a revolutionary intraoperative imaging system that gives surgeons real-time visual feedback of residual cancer in the tumor bed. Lumicell’s surgical system includes a margin-targeted injectable imaging agent and a novel hand-held imaging device with exquisite single-cell detection. The unprecedented ability to see and remove all cancer cells during the initial surgery has the potential to significantly improve surgical outcomes and reduce healthcare costs by eliminating the need for repeat surgeries. Lumicell is initially investigating its imaging system in patients undergoing surgery for breast cancer and sarcomas. Additional future indications will include surgeries for lung, prostate, ovarian, colorectal and brain cancers. For more information, please visit www.lumicell.com. Manage Cookie Consent To provide the best experience, we use technologies such as cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent may adversely affect certain features and functions. Functional Functional Always active The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network. Preferences Preferences The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user. Statistics Statistics The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you. Marketing Marketing The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. Manage options Manage services Manage {vendor_count} vendors Read more about these purposes Accept Deny View preferences Save preferences View preferences {title} {title} {title} Manage consent

The release as fetched from its publisher. lumicell.com ↗